However, a significant expansion of KIR2DL1+ CD8+ T cells, but no expansion of other KIR+ CD8+ T cell subsets, was observed in cancer patients in the presence of their specific HLA-C2 ligand (2.2% vs. 0.84%, p = 0.009, C1C2/C2C2 vs. C1C1 patients) (Figure 1C), while no significant differences among KIR+ CD8+ T cell subsets were detected in the presence of HLA-Bw4 ligands (Figure 1D) or HLA-C1 ligands. Here, KIR3DL1 is linked to cancer.